Regeneron Pharmaceuticals has won a patent case against Novartis AG in a United States court, over pre-filled syringes for anti-VEGF medication used to treat degenerative eye diseases.
Novartis, maker of Lucentis and Beovu, had filed a complaint against Regeneron, maker of Eylea. Novartis claimed it had a valid patent for pre-filled syringes, taking issue with Regeneron’s introduction of a competing pre-filled syringe, designed to treat the same disease, into the market.
the U.S. Patent Trial and Appeal Board ruled that Novartis’ pre-filled syringe for injecting its eye medication Lucentis was “unpatentable”
But in a victory for Regeneron, the U.S. Patent Trial and Appeal Board ruled that Novartis’ pre-filled syringe for injecting its eye medication Lucentis was “unpatentable”.
Eylea, a treatment for age-related macular degeneration, generates billions of dollars in annual sales for Regeneron.
In another win for Regeneron, the U.S. Food and Drug Administration has signed off on Eylea as a treatment for retinopathy of prematurity (ROP).2
The ruling makes Eylea the only pharmacologic treatment for ROP, which is otherwise treated by laser surgery.
References
- https://ophthalmologybreakingnews.com/regeneron-wins-patent-case-against-novartis-for-its-eye-drug-eylea-
- https://www.fiercepharma.com/pharma/regeneron-bayer-win-another-fda-nod-powerhouse-eylea
